# Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)

> **NCT00733122** · PHASE3 · WITHDRAWN · sponsor: **Merck Sharp & Dohme LLC**

## Conditions studied

- HPV Infections

## Interventions

- **BIOLOGICAL:** Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine

## Key facts

- **NCT ID:** NCT00733122
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-10-01
- **Primary completion:** 2013-10-01
- **Final completion:** 2013-10-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Following the direction of the local (India) health authority, data specified in the protocol were not collected and study was cancelled.
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00733122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00733122, "Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00733122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*